{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:34:58Z","timestamp":1789824898285,"version":"4.0.1"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Adenovirus infections of immunocompromised patients can develop into deadly multiorgan or systemic disease. The virus is especially threatening for pediatric allogeneic hematopoietic stem cell transplant recipients; according to some studies, 10% or more of these patients succumb to disease resulting from adenovirus infection. At present, there is no drug approved for the treatment or prevention of adenovirus infections. Compounds that are approved to treat other virus infections are used off-label to combat adenovirus, but only anecdotal evidence of the efficacy of these drugs exists. Ganciclovir, a drug approved for the treatment of herpesvirus infection, was previously reported to be effective against human adenoviruses\n            <jats:italic>in vitro<\/jats:italic>\n            . To model adenovirus infections in immunocompromised humans, we examined ganciclovir's efficacy in immunosuppressed Syrian hamsters intravenously infected with type 5 human adenovirus (Ad5). This animal model is permissive for Ad5 replication, and the animals develop symptoms similar to those seen in humans. We demonstrate that ganciclovir suppresses Ad5 replication in the liver of infected hamsters and that it mitigates the consequences of Ad5 infections in these animals when administered prophylactically or therapeutically. We show that ganciclovir inhibits Ad5 DNA synthesis and late gene expression. The mechanism of action for the drug is not clear; preliminary data suggest that it exerts its antiadenoviral effect by directly inhibiting the adenoviral DNA polymerase. While more extensive studies are required, we believe that ganciclovir is a promising drug candidate to treat adenovirus infections. Brincidofovir, a drug with proven activity against Ad5, was used as a positive control in the prophylactic experiment.\n          <\/jats:p>","DOI":"10.1128\/aac.03860-14","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T08:27:40Z","timestamp":1410856060000},"page":"7171-7181","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":47,"title":["Ganciclovir Inhibits Human Adenovirus Replication and Pathogenicity in Permissive Immunosuppressed Syrian Hamsters"],"prefix":"10.1128","volume":"58","author":[{"given":"Baoling","family":"Ying","sequence":"first","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology &amp; Immunology, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Tollefson","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology &amp; Immunology, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline F.","family":"Spencer","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology &amp; Immunology, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lata","family":"Balakrishnan","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Department of Biochemistry and Biophysics, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Dewhurst","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Department of Microbiology &amp; Immunology, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Capella","sequence":"additional","affiliation":[{"name":"The Ohio State University, Nationwide Childrens' Hospital, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Mark L.","family":"Buller","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology &amp; Immunology, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoly","family":"Toth","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology &amp; Immunology, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S. M.","family":"Wold","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology &amp; Immunology, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","first-page":"1704","volume-title":"Fields virology","author":"Berk AJ","year":"2013","unstructured":"BerkAJ. 2013. Adenoviridae, p 1704\u20131731. In KnipeDMHowleyPMCohenJIGriffinDELambRAMartinMARacanielloVRRoizmanB (ed), Fields virology, 6th ed (electronic). Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"6"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.003087-0"},{"key":"e_1_3_3_4_2","first-page":"1732","volume-title":"Fields virology","author":"Wold WSM","year":"2013","unstructured":"WoldWSMIsonMG. 2013. Adenoviruses, p 1732. In KnipeDMHowleyPMCohenJIGriffinDELambRAMartinMARacanielloVRRoizmanB (ed), Fields virology, 6th ed (electronic). Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"6"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702555"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/505498"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00052-07"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-259291"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.589"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.836964"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1556\/OH.2012.29496"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.09.007"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.04.007"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-398342-8.00003-3"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800200105"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3497"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.156"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2009.5"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2009.6"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.04.023"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/10.Supplement_3.S490"},{"key":"e_1_3_3_22_2","first-page":"338","volume-title":"Fields virology","author":"Coen DM","year":"2013","unstructured":"CoenDMRichmanDD. 2013. Antiviral agents, p 338\u2013373. In KnipeDMHowleyPMCohenJIGriffinDELambRAMartinMARacanielloVRRoizmanB (ed), Fields virology, 6th ed, vol 1 (electronic). Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"6"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1010-1016.2005"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199409000-00011"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(96)06966-5"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.1.55"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(89)95214-6"},{"key":"e_1_3_3_28_2","first-page":"2132","article-title":"Molecular epidemiology of adenoviral keratoconjunctivitis in Saudi Arabia","volume":"16","author":"Tabbara KF","year":"2010","unstructured":"TabbaraKFOmarNHammoudaEAkanumaMOhguchiTArigaTTagawaYKitaichiNIshidaSAokiKIshikoHOhnoS. 2010. Molecular epidemiology of adenoviral keratoconjunctivitis in Saudi Arabia. Mol. Vis. 16:2132\u20132136.","journal-title":"Mol. Vis."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(91)90054-U"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1988.tb02753.x"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.11.001"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00102-2"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01311-07"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700997"},{"key":"e_1_3_3_35_2","first-page":"295","article-title":"Adenovirus infection in a renal transplant patient","volume":"24","author":"Blohme I","year":"1992","unstructured":"BlohmeINybergGJeanssonSSvalanderC. 1992. Adenovirus infection in a renal transplant patient. Transplant. Proc. 24:295.","journal-title":"Transplant. Proc."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)85997-9"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300064"},{"key":"e_1_3_3_38_2","first-page":"169","volume-title":"Methods in molecular medicine","author":"Thomas MA","year":"2007","unstructured":"ThomasMASpencerJFWoldWSM. 2007. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors, p 169\u2013183. In TollefsonAEWoldWSM (ed), Methods in molecular medicine, 2nd ed, vol 1. Humana Press, Totowa, NJ.","edition":"2"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90175-9"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.17.2.360-364.1983"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1385\/1-59745-166-5:41"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00739-12"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.146894"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(80)90362-1"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.22.2.527-539.1977"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.60.2.353-362.1986"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283477cb5"},{"key":"e_1_3_3_48_2","first-page":"441","article-title":"Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes","volume":"1","author":"Colin J","year":"2007","unstructured":"ColinJ. 2007. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin. Ophthalmol. 1:441\u2013453.","journal-title":"Clin. Ophthalmol."},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2011.0475"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492011000600007"},{"key":"e_1_3_3_51_2","volume-title":"Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","author":"Center for Drug Evaluation and Research","year":"2005","unstructured":"Center for Drug Evaluation and Research. 2005, posting date. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Center for Drug Evaluation and Research Food and Drug Administration, Rockville, MD."},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(87)33534-1"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.5.4.446-450.1970"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.2.10.1295-1298.1982"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700638"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1638"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03860-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03860-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:44:41Z","timestamp":1645483481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03860-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1128\/AAC.03860-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03860-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"2014-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}